These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 28288121)

  • 41. K13-Mediated Reduced Susceptibility to Artemisinin in Plasmodium falciparum Is Overlaid on a Trait of Enhanced DNA Damage Repair.
    Xiong A; Prakash P; Gao X; Chew M; Tay IJJ; Woodrow CJ; Engelward BP; Han J; Preiser PR
    Cell Rep; 2020 Aug; 32(5):107996. PubMed ID: 32755588
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A brief history of artemisinin: Modes of action and mechanisms of resistance.
    Lu F; He XL; Richard C; Cao J
    Chin J Nat Med; 2019 May; 17(5):331-336. PubMed ID: 31171267
    [TBL] [Abstract][Full Text] [Related]  

  • 43. K13-Propeller Polymorphisms in Plasmodium falciparum Isolates from Patients in Mayotte in 2013 and 2014.
    Torrentino-Madamet M; Collet L; Lepère JF; Benoit N; Amalvict R; Ménard D; Pradines B
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7878-81. PubMed ID: 26416865
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prevalence of molecular markers of sulfadoxine-pyrimethamine and artemisinin resistance in Plasmodium falciparum from Pakistan.
    Yaqoob A; Khattak AA; Nadeem MF; Fatima H; Mbambo G; Ouattara A; Adams M; Zeeshan N; Takala-Harrison S
    Malar J; 2018 Dec; 17(1):471. PubMed ID: 30558587
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Drug resistance. K13-propeller mutations confer artemisinin resistance in Plasmodium falciparum clinical isolates.
    Straimer J; Gnädig NF; Witkowski B; Amaratunga C; Duru V; Ramadani AP; Dacheux M; Khim N; Zhang L; Lam S; Gregory PD; Urnov FD; Mercereau-Puijalon O; Benoit-Vical F; Fairhurst RM; Ménard D; Fidock DA
    Science; 2015 Jan; 347(6220):428-31. PubMed ID: 25502314
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In Vitro and Molecular Surveillance for Antimalarial Drug Resistance in Plasmodium falciparum Parasites in Western Kenya Reveals Sustained Artemisinin Sensitivity and Increased Chloroquine Sensitivity.
    Lucchi NW; Komino F; Okoth SA; Goldman I; Onyona P; Wiegand RE; Juma E; Shi YP; Barnwell JW; Udhayakumar V; Kariuki S
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7540-7. PubMed ID: 26392510
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Molecular Surveillance for Polymorphisms Associated with Artemisinin-Based Combination Therapy Resistance in
    Lucchi NW; Abdallah R; Louzada J; Udhayakumar V; Oliveira-Ferreira J
    Am J Trop Med Hyg; 2020 Feb; 102(2):310-312. PubMed ID: 31833470
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Spatial and molecular mapping of Pfkelch13 gene polymorphism in Africa in the era of emerging Plasmodium falciparum resistance to artemisinin: a systematic review.
    Kayiba NK; Yobi DM; Tshibangu-Kabamba E; Tuan VP; Yamaoka Y; Devleesschauwer B; Mvumbi DM; Okitolonda Wemakoy E; De Mol P; Mvumbi GL; Hayette MP; Rosas-Aguirre A; Speybroeck N
    Lancet Infect Dis; 2021 Apr; 21(4):e82-e92. PubMed ID: 33125913
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Multi-omics Based Identification of Specific Biochemical Changes Associated With PfKelch13-Mutant Artemisinin-Resistant Plasmodium falciparum.
    Siddiqui G; Srivastava A; Russell AS; Creek DJ
    J Infect Dis; 2017 May; 215(9):1435-1444. PubMed ID: 28368494
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dihydroartemisinin-piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study.
    Spring MD; Lin JT; Manning JE; Vanachayangkul P; Somethy S; Bun R; Se Y; Chann S; Ittiverakul M; Sia-ngam P; Kuntawunginn W; Arsanok M; Buathong N; Chaorattanakawee S; Gosi P; Ta-aksorn W; Chanarat N; Sundrakes S; Kong N; Heng TK; Nou S; Teja-isavadharm P; Pichyangkul S; Phann ST; Balasubramanian S; Juliano JJ; Meshnick SR; Chour CM; Prom S; Lanteri CA; Lon C; Saunders DL
    Lancet Infect Dis; 2015 Jun; 15(6):683-91. PubMed ID: 25877962
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The MSPDBL2 codon 591 polymorphism is associated with lumefantrine in vitro drug responses in Plasmodium falciparum isolates from Kilifi, Kenya.
    Ochola-Oyier LI; Okombo J; Mwai L; Kiara SM; Pole L; Tetteh KK; Nzila A; Marsh K
    Antimicrob Agents Chemother; 2015 Mar; 59(3):1770-5. PubMed ID: 25534732
    [TBL] [Abstract][Full Text] [Related]  

  • 52. K-13 propeller gene polymorphisms isolated between 2014 and 2017 from Cameroonian Plasmodium falciparum malaria patients.
    Eboumbou Moukoko CE; Huang F; Nsango SE; Kojom Foko LP; Ebong SB; Epee Eboumbou P; Yan H; Sitchueng L; Garke B; Ayong L
    PLoS One; 2019; 14(9):e0221895. PubMed ID: 31479501
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phenotypic and genotypic characterization of Thai isolates of Plasmodium falciparum after an artemisinin resistance containment project.
    Thita T; Jadsri P; Thamkhantho J; Ruang-Areerate T; Suwandittakul N; Sitthichot N; Mahotorn K; Tan-Ariya P; Mungthin M
    Malar J; 2018 May; 17(1):197. PubMed ID: 29764451
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Changes in the frequencies of Plasmodium falciparum dhps and dhfr drug-resistant mutations in children from Western Kenya from 2005 to 2018: the rise of Pfdhps S436H.
    Pacheco MA; Schneider KA; Cheng Q; Munde EO; Ndege C; Onyango C; Raballah E; Anyona SB; Ouma C; Perkins DJ; Escalante AA
    Malar J; 2020 Oct; 19(1):378. PubMed ID: 33092587
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evolution of Antimalarial Drug Resistance Markers in the Reservoir of Plasmodium falciparum Infections in the Upper East Region of Ghana.
    Narh CA; Ghansah A; Duffy MF; Ruybal-Pesántez S; Onwona CO; Oduro AR; Koram KA; Day KP; Tiedje KE
    J Infect Dis; 2020 Oct; 222(10):1692-1701. PubMed ID: 32459360
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Oxidative stress and protein damage responses mediate artemisinin resistance in malaria parasites.
    Rocamora F; Zhu L; Liong KY; Dondorp A; Miotto O; Mok S; Bozdech Z
    PLoS Pathog; 2018 Mar; 14(3):e1006930. PubMed ID: 29538461
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CRISPR/Cas9 system in Plasmodium falciparum using the centromere plasmid.
    Payungwoung T; Shinzawa N; Hino A; Nishi T; Murata Y; Yuda M; Iwanaga S
    Parasitol Int; 2018 Oct; 67(5):605-608. PubMed ID: 29886342
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Resistance screening and trend analysis of imported falciparum malaria in NSW, Australia (2010 to 2016).
    Prosser C; Meyer W; Ellis J; Lee R
    PLoS One; 2018; 13(5):e0197369. PubMed ID: 29813085
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Novel pfkelch13 Gene Polymorphism Associates With Artemisinin Resistance in Eastern India.
    Das S; Manna S; Saha B; Hati AK; Roy S
    Clin Infect Dis; 2019 Sep; 69(7):1144-1152. PubMed ID: 30535043
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Assessment of Plasmodium falciparum anti-malarial drug resistance markers in pfk13-propeller, pfcrt and pfmdr1 genes in isolates from treatment failure patients in Democratic Republic of Congo, 2018-2019.
    Yobi DM; Kayiba NK; Mvumbi DM; Boreux R; Kabututu PZ; Situakibanza HNT; Umesumbu SE; De Mol P; Speybroeck N; Mvumbi GL; Hayette MP
    Malar J; 2021 Mar; 20(1):144. PubMed ID: 33706773
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.